My Account Log in

4 options

Perspectives on biomarker and surrogate endpoint evaluation : discussion forum summary / Alison Mack, Erin Balogh, and Christine M. Micheel ; Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease.

EBSCOhost Academic eBook Collection (North America) Available online

View online

Ebook Central Academic Complete Available online

View online

NCBI Bookshelf Available online

View online

National Academies Press Available online

View online
Format:
Book
Author/Creator:
Mack, Alison.
Contributor:
Balogh, Erin.
Micheel, Christine.
Institute of Medicine (U.S.). Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease.
Language:
English
Subjects (All):
Biochemical markers.
Physical Description:
1 online resource (139 p.)
Edition:
1st ed.
Place of Publication:
Washington, D.C. : National Academies Press, 2011.
Language Note:
English
Summary:
In 2010 the Institute of Medicine (IOM) recommended a framework for the evaluation of biomarkers in the chronic disease setting. Published in the book Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease, the framework is intended to bring consistency and transparency to the previously disparate process of biomarker evaluation. Following the book's release, the IOM convened a 2-day discussion forum in Washington, DC, in order to provide an opportunity for stakeholders to learn about, react to, and discuss the book. Presentations reviewed the authoring committee's work process, recommendations, and provided perspectives on the book from the point of view of participants. Thomas Fleming, professor of biostatistics and statistics at the University of Washington, gave a keynote presentation on the critical issues in the validation of surrogate endpoints, a specific use of a biomarker. The present volume recounts the discussion forum proceedings, focusing in turn on each represented sector. A summary of Dr. Fleming's presentation then sets the committee's recommendations within the context of biomarker utilization. Lastly, this summary examines the main themes raised by stakeholders, and the challenges and opportunities presented to stakeholders by the book's recommendations.-- Source other than Library of Congress.
Contents:
Introduction
Committee findings and recommendations
FDA perspectives
National institutes of health perspectives
Industry perspectives
Public health, consumer, and consulting organization perspectives
Presentation by Thomas Fleming: biomarkers and surrogate endpoints in chronic disease
Key themes, challenges, and opportunities
Importance of the biomarker discussion forum.
Notes:
Bibliographic Level Mode of Issuance: Monograph
Includes bibliographical references (p. 99-102).
ISBN:
9786612976056
9780309187008
0309187001
9781282976054
1282976052
9780309163255
0309163250
OCLC:
707927323

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account